
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize therapeutics for unmet medical needs and has demonstrated potential for growth with a strong pipeline of products. The positive results from the company's studies and strong management outlook for their products, as well as the potential for future partnerships and acquisitions, make Alkermes a promising investment opportunity with a potential to generate strong returns for investors in the long term.
Bears say
Alkermes is facing challenges in adequately defining the patient population for its narcolepsy treatment and may face limitations on the initial label. The company's upcoming Phase 2 ADHD trial, while promising, will not have results available for several years and may face competition from both non-stimulant and stimulant treatments. Safety concerns, such as poliuria and insomnia, may also pose risks to the success of Alkermes's products.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares